retatrutide nonalcoholic fatty liver disease nash trial Xia & He Publishing Analysis of NASH Underscores Need

The GLP-1 receptor agonist component is considered the likely contributor to gastrointestinal side effects, based on established class-effect data from semaglutide and tirzepatide

Patients should be cautious of online suppliers offering tesamorelin without a valid prescription, as the quality, purity, and safety of such products cannot be guaranteed

2024 Feb 15;29(4):865

Boasting about "no gym" when we know muscle loss is a problem with GLP-1s

We will have one coming out in 2026, 27

The decision establishes the procedural framework for early motions, discovery planning, and potential coordination with the ongoing GLP-1 stomach injury proceedings as the NAION litigation progresses